The trial that moved the stock
Genmab said late Friday that Rina-S delivered a 71 percent reduction in the probability of progression or death in patients with platinum-resistant ovarian cancer. The study cleared its main objective and key secondary measures, topping what analysts were modeling and bolstering confidence in the pipeline.
Separately on Sunday, the company reported encouraging news on petosemtamab, a therapy it is advancing in head and neck and colorectal cancers.
Market reaction and analyst moves
Shares rose as much as 14% on Monday in Copenhagen, the biggest intraday gain since March 2020. The stock is now up more than 45% in 2026, ranking third in Denmark's C25 behind Demant A/S and AP Moller-Maersk A/S.
"Genmab has hit two home runs with the first two major news catalysts of the fourth quarter," Jyske Bank's Henrik Hallengreen Laustsen wrote, boosting his price target by 24% to 2,925 kroner and maintaining a hold rating. Jefferies analysts, among them Benjamin Jackson, said Rina-S's implied efficacy topped their "transformative" scenario. Van Lanschot Kempen also raised its target, and JPMorgan shifted the shares to overweight from neutral and set a 3,500 kroner target.
When news moves individual stocks, staying informed matters, so sign up for the free Market Briefs for clear updates each morning.
Why it matters for your portfolio
The latest wins add to a run of favorable pipeline updates, dialing down uncertainty around programs slated to power Genmab's next growth phase. The company has been moving beyond Darzalex royalty income, building a broader cancer portfolio, and AL Sydbank's Soren Lontoft Hansen said the strong Rina-S data, together with that wider lineup, could help offset an expected decline in Darzalex royalties toward the end of the decade.
With complex news flows, let the free Market Briefs newsletter deliver a concise daily snapshot of the economy and markets.
